Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults

Jeeyeon Kim1, Miesha Farahmand1, Colleen Dunn2, Carlos E. Milla2, Rina I. Horii3, Ewart A. C. Thomas3, Richard B. Moss2 & Jeffrey J. Wine1,2,3

To determine if ivacaftor (Kalydeco) influences non-CF human CFTR function in vivo, we measured CFTR-dependent (C-sweat) and CFTR-independent (M-sweat) rates from multiple identified sweat glands in 8 non-CF adults. The two types of sweating were stimulated sequentially with intradermal injections of appropriate reagents; each gland served as its own control via alternating off-on drug tests on both arms, given at weekly intervals with 3 off and 3 on tests per subject. We compared drug effects on C-sweating stimulated by either high or low concentrations of β-adrenergic cocktail, and on methacholine-stimulated M-sweating. For each subject we measured ~700 sweat volumes from ~75 glands per arm (maximum 12 readings per gland), and sweat volumes were log-transformed for statistical analysis. T-tests derived from linear mixed models (LMMs) were more conservative than the familiar paired sample t-tests, and show that ivacaftor significantly increased C-sweating stimulated by both levels of agonist, with a larger effect in the low cocktail condition; ivacaftor did not increase M-sweat. Concurrent sweat chloride tests detected no effect of ivacaftor. We conclude that ivacaftor in vivo increases the open channel probability (PO) of WT CFTR, provided it is not already maximally stimulated.

The genetic disease cystic fibrosis (CF) is caused by mutations that affect CFTR anion channels. Some gating mutations decrease CFTR’s average open probability (PO) with little or no effect on channel number. In vitro, the PO of many gating mutations is increased by ivacaftor (VX-770)1,2, and when treated with orally available ivacaftor (Kalydeco) most CF patients with gating mutations show marked clinical improvement3–6. Ivacaftor used acutely in vitro also increases the PO of normal human wild type (WT) CFTR1,7,8. However, the effect of chronic exposure to ivacaftor (24 hr or more) on WT or corrected F508del CFTR is uncertain. Additional in vitro studies have suggested either that it does not potentiate function of F508del or WT CFTR9, or that it actually decreases function10. At least for F508del the decrease with chronic ivacaftor is related to drug concentration, and was not observed using drug levels expected in vivo11. In vitro conditions differ in many respects from in vivo ones, and so we sought to determine if chronic oral ivacaftor dosing, taken as directed as a treatment for CFTR gating mutations, would increase, decrease or fail to affect WT CFTR function in non-CF adult subjects.

Another motivation for this work was to explore additional methods for assessing modulator effects on CFTR function in vivo, because no existing method is optimal across all conditions12. For example, FEV1 tests are insensitive when lung disease is either too mild or too severe. The ‘sweat test’ i.e. the chloride concentration in eccrine sweat, is a mainstay of in vivo CFTR functional assessment13,14, but also possess idiosyncratic features15, some of which may have contributed to unexpected results in a study of combined treatment with lumacaftor (VX-809) and ivacaftor16. In one arm of that study, 28 days of lumacaftor were followed by 28 days of lumacaftor + ivacaftor. While FEV1 improved during combination treatment vs monotherapy, sweat chloride concentration did not.

Why should this be? One possibility is that CFTR function in the sweat duct differs from its function in airway epithelia16. Indeed, the sweat duct has several features that suggest caution when extrapolating from sweat chloride levels to CFTR function in other organs: it is an exclusively absorptive organ; it absorbs hypertonically (salt > water); uniquely for epithelia it consists of a double layer of epithelial cells, and CFTR is expressed on both apical and basolateral membranes in the duct17–20. Also, sweat chloride levels have a logarithmic relation to CFTR.

1Cystic Fibrosis Research Laboratory, Stanford University, Stanford, CA, 94305, USA. 2Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA. 3Department of Psychology, Stanford University, Stanford, CA, 94305, USA. Correspondence and requests for materials should be addressed to J.J.W. (email: wine@stanford.edu)
function, making the assay progressively less sensitive at higher levels of CFTR function, being almost flat from 50–100% function\textsuperscript{1}. Moreover, CFTR is fully activated in perfused sweat ducts, and cannot be further activated by agents that activate CFTR in other tissues\textsuperscript{22}. Sweat duct conductance, due mainly to Cl\textsuperscript{−} conductance through CFTR, is among the highest known for any tissue (125 ± 14 mS/cm\textsuperscript{2})\textsuperscript{32} indicating that CFTR is abundant and probably has a high P\textsubscript{o}, because CFTR channels show cooperativity, with higher P\textsubscript{o} values occurring when channel density is high\textsuperscript{33}. Some combination of these features may help explain why, for ivacaftor monotherapy with G551D subjects, there was no relationship between Δ sweat chloride and Δ FEV\textsubscript{1}\textsuperscript{25}.

Given these issues, we set out to assess ivacaftor effects on human WT CFTR function \textit{in vivo} using two complementary assays: sweat chloride levels\textsuperscript{26} and CFTR-dependent sweat rate (C-sweat). C-sweat is rate-limited by CFTR function in the sweat gland secretory coil: it is absent in people with CF\textsuperscript{27} and half normal in carriers\textsuperscript{28,29}, thus providing a near-linear readout of CFTR function. To help detect small differences in a small sample of subjects, we identified >100 individual sweat glands in each subject (>50 per arm) and used a repeated measures design where each gland served as its own control across 3 off and 3 on ivacaftor trials. In preliminary analyses of C-sweat rates, we considered only glands that were measured on all 6 tests, computed the average response on the 3 off drug tests and that on the 3 on drug tests, and then conducted a paired samples t-tests on these averages. For the main analyses, we fitted linear mixed models (LMMs) to the data from \textit{all} glands. These LMMs included variance parameters for the random variation across glands and testing occasions (i.e., weeks), and the resulting t-tests were more conservative than the paired samples t-tests. We present both sets of results. As an additional control, for each gland we also obtained sweat rates to the muscarinic agonist methacholine (M-sweat); sweating induced by this pathway does not require CFTR\textsuperscript{27}. To determine if the P\textsubscript{o} of WT CFTR \textit{in vivo} might be near maximal before ivacaftor (a ceiling effect) we stimulated C-sweating with two concentrations of a β\textsubscript{2}-adrenergic cocktail: a saturating dose\textsuperscript{21}, and another that was 1% of the saturating dose.

Our results show that chronic (4 day) ivacaftor treatment \textit{in vivo} increased WT CFTR function, confirming results seen with acute ivacaftor \textit{in vitro}\textsuperscript{1,4}. The increase is blunted at the higher dose of agonist. Of note, we did not detect a change in sweat chloride levels for subjects on ivacaftor.

**Methods**

Extended methods are presented in electronic Supplementary Material.

**Study Approval.** The study (ClinicalTrials.gov: NCT02310789, 03/09/2014) was performed in accordance with all relevant guidelines/regulations, including obtaining informed consent from all participants, and was approved by Stanford University Institutional Review Board #4. After written informed consent, 8 subjects were studied: 5 non-CF adults with ‘wild type’ CFTR (no CF mutations in a screen for the 39 most common mutations) and 3 CF carriers with one CFTR mutation (all F508del).

**Study Design.** We compared responses for the same identified glands off and on drug. A pilot experiment (Fig. 1a) interposed multiple weeks of off drug testing to look for washout effects, but most subjects were tested with 3 off and 3 on drug tests alternating at weekly intervals (Fig. 1b), with the last dose of ivacaftor taken on the morning of the test day (Fig. 1c). Results were assessed with linear mixed models (LMMs, Fig. 1d) as the main analysis for all data, and also with Supplementary paired t-tests.

**Measurement of sweat secretion from identified individual glands.** We used a modified version of the single gland, optical imaging assay for CFTR secretory function as described\textsuperscript{29}. The assay depends on two parallel pathways for sweat secretion (Fig. 2): a CFTR-independent, cholinergic pathway stimulated with methacholine (‘M-sweat’) and a β\textsubscript{2}-adrenergic pathway that is CFTR-dependent (‘C-sweat’). When C-sweating is expressed as a function of M-sweating, it gives a near-linear readout of CFTR function over a wide range: e.g., the C-sweat/M-sweat ratio for CF carriers is 50% that of non-CF controls, and the ratio for CF subjects is zero\textsuperscript{28,29}. Examples of the two types of sweat are shown in Fig. 3.

**Sweat chloride collection and measurement.** Sweat samples were stimulated via pilocarpine electrophoresis and collected using the Macroduct 3700 sweat collection system (Wescor Inc., Logan, UT) according to standard procedures, i.e. 5 min of stimulation and 30 min collection. One sample was collected from each subject on each study visit. Sweat chloride was measured using the QuantiChrom Chloride Assay Kit (BioAssay Systems, Hayward, CA) in accordance with the manufacturer’s instructions. Optical density (OD) of the samples and standards were read at 610 nm with a SpectraMax Plus 384 microplate reader (Molecular Devices, San Francisco, CA). Standard OD values were subtracted from the blank OD measurement, and were plotted against a curve of OD measurements of 8 Cl\textsuperscript{−} concentration standards from 0 to 35 (mg/dL). A slope was determined from the linear regression to convert sample OD values into final Cl\textsuperscript{−} concentrations (mmol/L).

**Statistics.** We used two statistical approaches to evaluate the sweat secretion data. We applied linear mixed effects models (LMMs) to the log transformed data from \textit{all} glands, using the package, \texttt{lme4}\textsuperscript{40}, in the R language and environment\textsuperscript{41}. In these multi-factorial regression analyses, results were considered significant if \( P \leq 0.05 \). We present the \texttt{lme4} syntax for the various LMMs that we used, so as to facilitate replication of our analyses by other researchers, in Electronic Supplementary Material. For a subset of glands present across all 3 off and all 3 on drug tests, we also used paired t-tests of log transformed data to test for significance within subjects, with results considered significant if \( P \leq 0.001 \) (using Bonferroni correction for a familywise false alarm rate of ~0.05 across tests). The number of glands used in these paired-comparisons averaged 43 to 48 glands per arm (Supplementary Table 1), much less than the ~75 glands per arm that are included in the mixed models analyses. Gland responses were not measured on some trials because of merging of bubbles, poor images, or non-optimal placement of the
reservoir. The requirement that a gland be measured across all M-sweat or all C-sweat tests to allow for paired t-tests resulted in ~40% of the data being ignored.

Results

Experiment 1 (pilot). S1, male, WT/F508del, was tested at left and right arm sites, with up to 74 glands identified at each site. A linear mixed models (LMM) analysis using all glands from both arms indicated a significant increase on drug for S1 (Table 1). S2, female, WT/WT, was tested using the same paradigm, but after multiple weeks of testing, she developed what appeared to be a delayed sensitivity reaction at the injection sites (itching, redness) accompanied by a precipitous drop in responding, leading us to terminate testing (Supplementary Fig. 1). LMM analysis of 203 glands from both arms showed a non-significant increase of 10 ± 11% (Table 1).

Paired t-tests for both subjects are shown in Supplementary Table 1; they indicated significant increases for one arm from each subject that did not correlate with peak-trough tests. We saw no evidence for prolonged effects in either subject. To summarize Exp. 1, the mean C-sweat rates showed small, inconsistent increases on drug for both subjects. LMM analysis of combined arm results were significant for S1 but not S2, suggesting that any effect of drug on C-sweat was small enough to be partially obscured by random error in this small pilot study.

Experiment 2, full cocktail. Because differences in peak-trough values or washout effects were not evident, in Experiment 2 we tested 3 additional subjects alternately on and off drug at weekly intervals for a total of 3 off and 3 on drug tests (Fig. 1b), with the on drug tests occurring ~4–8 hrs after their last dose of ivacaftor. One subject was tested only on one arm because the other arm lacked a visible mark needed to register gland location. Thus, experiment 2 comprised 30 tests (5 sites × 6 tests).

S3, Female, WT/F508del, was tested only on her left arm. LMM analysis of the C-sweat increase on drug across both arms was 9.2 ± 10.6%, P = 0.434, 121 glands (LMM, n.s.). Results are summarized in Table 1 for LMM analyses; paired t-tests are shown in Supplementary Table 1.
To summarize Experiments 1 and 2, small, variable increases in C-sweat responding were produced by ivacaftor. LMM analyses (Table 1 and Fig. 4a), on pooled data (695 glands, 5 subjects) gave $P = 0.035$. The paired $t$-test analyses for each arm separately, shown in Supplementary Table 1, top panel, showed significant increases in C-sweat for 3/9 sites, non-significant increases for 5/9 sites and non-significant decrease as 1/9 sites. The small overall increase observed could result from saturation of the C-sweat rate caused by our use of a cocktail concentration that was designed to be maximal. This hypothesis was investigated in Experiment 3.

**Experiment 3: Stimulation with 1% cocktail concentration.** This experiment was identical to Experiment 2, except that we reduced the concentration of isoproterenol and aminophylline in the $\beta$-adrenergic cocktail to 1% of full cocktail, while keeping the same concentration of atropine to block muscarinic receptors. Any ivacaftor potentiation of WT CFTR should be more easily discerned if glands were secreting at sub-maximal rates. Results (all data log transformed) are summarized in Table 1, Fig. 4b, and Supplementary Table 1.

| Subject | Left Arm | Right Arm | Combined Sites |
|---------|----------|-----------|----------------|
| S1, M, WT/F508del | 11 ± 5% | 9.3E-10 | 5.40E-07 |
| S3 F, WT/F508del | 10.7 ± 3.9% | 4.55E-06 | 4.55E-06 |
| S6 F, WT/F508del | 12.4 ± 3.5% | 5.057 | 5.057 |

Figure 2. A simplified schematic diagram of ion channels responsible for anion-mediated sweat secretion. The sweat coil contains two types of anatomically distinct cell types, dark and light. Both cell types contain the machinery required to secrete anions in response to cholinergic stimulation: muscarinic receptors (M3), basolateral $Ca^{2+}$-activated $K^+$ channels and apical $Ca^{2+}$-activated chloride channels (CACC). Clear cells also contain $\beta_2$ adrenergic receptors ($\beta_2$AR) and pathways to elevate [cAMP]. (A) Cholinergic stimulation (mimicked by injection of methacholine) stimulates both cell types by increasing $[Ca^{2+}]$, and activating apical CACC channels, and, in clear cells, basolateral K$^+$ channels. (B) Adrenergic stimulation (mimicked by isoproterenol + aminophylline to elevate [cAMP], and atropine to prevent any activation of M3 receptors) activates CFTR in $\beta$-sensitive cells. Because CFTR levels are low and because no basolateral K$^+$ channel is activated by isoproterenol, anion efflux and hence fluid secretion is much smaller than it is to cholinergic stimulation. ($\beta$-sensitive cells can support anion efflux because they have a higher resting gK as indicated by their more hyperpolarized membrane potential). Diagram based on experiments by M. M. Reddy, & P. M. Quinton and by Sato & Sato.

To re-test with 1% cocktail. C-sweat secretion from both arms (all glands) was increased 11 ± 5% on ivacaftor (LMM, $P = 0.065$). Using paired t-test analyses, C-sweating increased by 18% on drug for both left (48 glands, $P = 9.3E-10$) and right arm sites (47 glands, $P = 5.40E-07$). For the combined sites, 89 of the 95 (94%) glands present across all tests showed increased C-sweat rates on drug. S3 F, WT/F508del (left arm only), was also re-tested with 1% cocktail. Her increase on drug was 10.7 ± 3.9%, (LMM, 94 glands, $P = 0.037$); or 9% (paired t-tests, 47 glands, $P = 4.55E-06$), with 42/47 (89%) of the glands showing increased C-sweating. S6 F, WT/F508del increased 12.4 ± 3.5% on drug (LMM, 178 glands, $P = 0.057$). With paired t-tests,
left arm C-sweat increased 16% (42 glands, \( P = 1.0 \times 10^{-6} \)) and right arm increased 9% (66 glands, \( P = 6.1 \times 10^{-11} \)).

For both sites, 91/108 (84%) of the glands increased on drug. S7, F, WT/WT increased 12.4 ± 3.5% (LMM, 181 glands, \( P = 0.016 \)). With paired t-tests, left arm increased 19% (57 glands, \( P = 3.2 \times 10^{-12} \)), and right arm 4% (63 glands, \( P = 0.080 \)). (Only 2 on drug tests were averaged for S7’s left arm site because one test produced no usable data owing to a technical failure). Across both sites 92/120 (77%) of glands increased on drug.

The last subject, S8, M, was recruited as a non-CF subject and like all other subjects tested negative for the 39 most common CFTR mutations. He had the lowest C-sweat/M-sweat ratio observed in this study—less than half the rate of two known carriers of CFTR mutations tested in the same way in this study. This subject’s response to ivacaftor was the largest we observed; a 37 ± 7.4% increase in C-sweat (LMM, 168 glands, \( P = 0.007 \)). With paired t-tests, the left arm increased 26% (26 glands, \( P = 3.5 \times 10^{-8} \)), and the right arm increased 44% (36 glands, \( P = 3.1 \times 10^{-12} \)). Across both arm sites 60 of 62 glands (97%) showed increased C-sweating on ivacaftor. The combination of low baseline C-sweating and large response to ivacaftor seen in S8 are unexplained; we cannot rule out the possibility that one allele of this subject might be a rare gating mutation that is not included in the screening panel of 39 CFTR mutations.

To summarize experiment 3, ivacaftor produced larger and more significant increases in C-sweating stimulated by 1% cocktail than it did for C-sweating stimulated with full cocktail. LMM analysis of pooled data from 762 glands showed log transformed C-sweat increasing by 16.45 ± 2.25% on drug (\( P = 6.8 \times 10^{-8} \), Table 1). Using paired t-tests the average increase was 18 ± 12% with all increases for single sites significant at \( P \leq 0.001 \), except for a non-significant 4% increase on the right arm of subject S7.

Ivacaftor effects on responses stimulated by full cocktail and 1% cocktail in the same glands and subjects. To assess the interaction between cocktail concentration and the level of ivacaftor more directly, we compared a set of glands at each of 3 sites from S1 and S3 that were measured throughout all 12 tests at both cocktail strengths (3 off/on with full and 3 off/on with 1% cocktail). For each site 28–39 glands (100 total glands) met the criterion. For all 3 sets of identical glands the effect size was larger with the reduced cocktail stimulus (Table 2), consistent with results from experiments across subjects, supporting the hypothesis that full cocktail increased CFTR \( \alpha \) to near maximal values, such that further increases produced by ivacaftor would be minimized (a ceiling effect). A bonus from this comparison is that S1 and S3 are both CF carriers with one non-functional F508del allele and therefore –half normal CFTR-dependent apical anion conductance. This makes it less likely that some other rate-limiting process could be responsible for the reduced effect size of ivacaftor with full-strength cocktail. This is consistent with other evidence that CFTR is rate-limiting for C-sweat. Another informal test of the moderation by agonist concentration (1% vs. full) of ivacaftor’s effect on C-sweat was obtained by directly comparing the average drug effects, 16.45% and 6.60%, at the 1% and full cocktail levels, respectively. These LMM estimates have an approximate \( t \) distribution with about 27 and 25 degrees of freedom, respectively (using the Satterthwaite approximation). In the LMM analysis section of the online Supplementary Data, we present a conservative Z-test for the difference in drug effects. This test yields \( z = 2.539 \) (\( p = 0.011 \)), supporting the conclusion that the drug effect is greater in the reduced cocktail stimulus.

Methacholine-stimulated sweat rates off and on ivacaftor. Every C-sweat test was preceded by an M-sweat test at the same site (see Methods). To assess ivacaftor effects on M-sweating we combined results across all experiments because stimulation of M-sweat followed the same protocol throughout, giving 18 comparisons from 8 subjects, based on 52 separate tests (each comparison based on triplicate tests except for S2, duplicate only) with 1457 identified glands. No significant increase of M-sweat secretion was detected in the presence of ivacaftor: the increase across all subjects was 2.1 ± 2.2% (\( P = 0.34 \), n.s., LMM analysis, Table 1, Column 3), and paired t-tests gave erratic results (−31% to +31%, Supplementary Table 2) with no significant overall trend. The inability to see an ivacaftor effect on M-sweating in non-CF subjects is consistent with the very small contribution of CFTR to apical anion conductance during cholinergic stimulation (Fig. 2A).
Sweat chloride values off and on ivacaftor. On each study visit in experiments 2 and 3, Macroduct sweat chloride testing was conducted on one arm, providing 3 off drug and 3 on drug measurements for each subject, except for S3, who was run in both experiments and so had 6 tests in each condition. Results are shown in Fig. 5. Four subjects showed decreases on drug and 3 showed increases, with no net change overall. The average values off and on drug were 24.9 \pm 6.1 and 25.1 \pm 11.4 respectively, yielding a difference that was not significant (P > 0.92) for either the paired t-test based on the 7 difference scores (1 for each subject), or the LMM based on the 48 measurements from the 7 subjects.

| By Subj. | C-sweat-Full |  | C-sweat-1% |  | M-sweat |  |
|----------|-------------|---|------------|---|---------|---|
|          | \(\Delta\) (%) | p  | N          | \(\Delta\) (%) | p  | N       | \(\Delta\) (%) | p  | N       |
| S1 \*    | 8.14 \pm 0.09*** | 0.0001 | 145 | 11.2 \pm 4.67% | 0.0653 | 141 | 5.86 \pm 2.51% | 0.0649 | 286 |
| S2       | 10.14 \pm 11.23 | 0.0581 | 203 | 2.89 \pm 11.24% | 0.8199 | 203 |                     |     |         |
| S3 \*    | 3.86 \pm 2.48 | 0.1607 | 97 | 10.66 \pm 3.89%* | 0.0369 | 94 | 0.545 \pm 1.69% | 0.7556 | 191 |
| S4       | 3.36 \pm 6.72 | 0.6405 | 129 | not done |                     |     | 7.0 \pm 6.73% | 0.3505 | 129 |
| S5       | 9.18 \pm 10.63 | 0.0430 | 121 | not done |                     |     | -14.48 \pm 10.6% | 0.2410 | 121 |
| S6 \*    | not done |                     |     | 12.05 \pm 4.66% | 0.0565 | 178 | -2.15 \pm 4.69% | 0.6690 | 178 |
| S7       | not done |                     |     | 12.4 \pm 3.48%* | 0.0159 | 181 | 11.73 \pm 3.49% | 0.0200 | 181 |
| S8       | not done |                     |     | 37.00 \pm 7.35%** | 0.0066 | 168 | 1.91 \pm 7.44% | 0.8098 | 168 |

Pooled Data

| By Subj. | C-sweat-Full |  | C-sweat-1% |  | M-sweat |  |
|----------|-------------|---|------------|---|---------|---|
|          | \(\Delta\) (%) | p  | N          | \(\Delta\) (%) | p  | N       | \(\Delta\) (%) | p  | N       |
| S1-S5    | 6.60 \pm 2.97%* | 0.0352 | 695 | 16.45 \pm 2.25%*** | 6.86e-8 | 762 | 2.38 \pm 2.66% | 0.421 | 1208 |

Table 1. Linear mixed models analyses of the change, \(\Delta\) (\(\pm 1\) s.e.), in sweat rate due to ivacaftor (‘Off’ versus ‘On’), by subject, type of sweat and, for C-sweat, cocktail concentration (‘Full’ versus ‘1%’). Results are shown for each Subject, combining data from both arms (except for S3, whose data came from 1 arm), and for the pooled data. N refers to the number of glands used in the mixed models analyses, and significance levels are denoted by “*”, for 0.01 < p < 0.05; “**”, for 0.001 < p < 0.01; and “***”, for p < 0.001.

**Figure 4.** Summary of sweat rate results for all glands analyzed with linear mixed models. (A) Log volume of C-sweat produced by 100% cocktail off and on ivacaftor. Each point represents the (\(\pm\)SE) results for all glands tested in the two conditions for the subjects shown. (B) Log volume of C-sweat produced by 1% cocktail off and on ivacaftor. (C) Log volume of M-sweat produced by methacholine off and on ivacaftor. For number of glands tested and statistical methods and significance see Table 1, based on the same data but presented as \(\Delta\) (%) on drug. Dashed lines and open circles indicate carriers of one F508del mutation. C-sweat volumes are based on 30 min of sweat collections and M-sweat on 10 min collection. Scales for A and B are equal.
Discussion
This research set out to answer five related questions. Two main questions were whether four days of oral ivacaftor (Kalydeco) would produce an increase in WT CFTR function, a decrease, or have no effect, and whether its effect would be altered by the concentration of the β-adrenergic cocktail used to stimulate CFTR. We also asked if ivacaftor would increase M-sweat rates, if the sweat rate assay was more sensitive for detecting changes in WT function than the sweat chloride assay, and if our conclusions held across the two statistical approaches.

As assessed with C-sweat rates, ivacaftor did increase WT CFTR function in vivo, and the effect size was increased using a weaker β-adrenergic cocktail to stimulate CFTR. We did not detect a significant effect of ivacaftor on M-sweat or on sweat chloride levels. The pattern of drug effects for sweat rates held both for linear mixed models (LMM) analyses and paired t-tests. The LMM analyses allowed for the estimation of week-to-week variability, separately from that of measurement error, and this led to a more conservative test of the drug effect. In other words, the paired t-ratio was inflated because it was based on a standard error of estimate that ignored week-to-week variability and was, therefore, too small. Further, the paired t-tests required about 40% of the glands to be ignored (because they weren’t measured in all tests), and this decreased the power of the test. For these reasons, our conclusions about sweat rates rely mainly on the LMM results. When assessing the drug effect on sweat chloride measurements, however, week-to-week variability was confounded with measurement error, because there was only 1 measurement per week in each drug condition, and the paired t-test was likely as conservative as the LMM. Not surprisingly, the two approaches yielded nearly identical results.

Ivacaftor potentiated WT CFTR in vivo with evidence for a ceiling effect. Ivacaftor potentiation was most evident when sub-maximal concentrations of the β-adrenergic cocktail were used (Table 1 and Fig. 4), presumably because the saturating concentration of β-adrenergic cocktail pushed CFTR P_o near to its maximum. The mean increase produced by ivacaftor (prior to log transformation) was 13 ± 16% for glands stimulated with full cocktail, vs. 41 ± 31% for glands stimulated with a sub-maximal β-adrenergic cocktail. The 13% increase is smaller than observed in vitro with acute addition of ivacaftor to forskolin-stimulated cells, where increases of 50–100% have been observed. In addition to acute vs. chronic addition, many other differences between the in vivo and in vitro experiments might explain the quantitative differences. The present approach is important because it shows that ivacaftor potentiates WT CFTR in vivo when used as directed. Because of evidence that smoking suppresses CFTR, this finding supports the proposal that ivacaftor could be useful for the treatment of smoking related COPD.

An ivacaftor effect was not detected on sweat chloride levels. Sweat chloride levels were not decreased by ivacaftor in these non-CF subjects. This is not surprising for two reasons. First, sweat chloride provides a logarithmic readout of CFTR function, falling steeply from ~100 mM when CFTR function is zero to ~40 mM

| Subj | Arm | N   | Full Cocktail stimulus | 1% Cocktail stimulus |
|------|-----|-----|------------------------|----------------------|
|      |     | n↑  | Δ (%) | P value | n↑  | Δ (%) | P value |
| S1   | L   | 28  | 17/28 | 2%     | 0.44 | 25/28 | 18% | 1E-05 |
| S1   | R   | 33  | 30/33 | 8%     | 0.008 | 30/33 | 14% | 2E-04 |
| S3   | L   | 39  | 27/39 | 3%     | 0.223 | 30/39 | 10% | 3E-05 |

Table 2. Paired t-tests on the change, Δ, in C-sweat rate due to ivacaftor (‘Off’ versus ‘On’) in identical sets of glands, for S1 (each arm) and S3 (left arm), at each cocktail concentration (‘Full’ versus ‘1%’). N refers to the number of glands used in the t-tests, and n↑ refers to the fraction of glands showing an increase due to ivacaftor. The estimates of Δ are in line with those in Table 1, but the p-values are likely too small, as argued in the Discussion.

Figure 5. Average sweat chloride values off and on Kalydeco for each subject and averaged for all subjects. For S1, S2 and S4-S8, each gray bar represents the mean ± SD of 3 off drug tests and each red bar the mean ± SD of 3 on-drug tests. S3 was tested in both experiments 2 and 3 so each bar represents the mean of 6 tests. Sweat chloride values were not obtained for S2 who was only run in the pilot experiment (Exp. 1). Grand means for all 7 subjects are shown with bold bars labeled ‘All’.

Ivacaftor potentiated WT CFTR in vivo with evidence for a ceiling effect. Ivacaftor potentiation was most evident when sub-maximal concentrations of the β-adrenergic cocktail were used (Table 1 and Fig. 4), presumably because the saturating concentration of β-adrenergic cocktail pushed CFTR P_o near to its maximum. The mean increase produced by ivacaftor (prior to log transformation) was 13 ± 16% for glands stimulated with full cocktail, vs. 41 ± 31% for glands stimulated with a sub-maximal β-adrenergic cocktail. The 13% increase is smaller than observed in vitro with acute addition of ivacaftor to forskolin-stimulated cells, where increases of 50–100% have been observed. In addition to acute vs. chronic addition, many other differences between the in vivo and in vitro experiments might explain the quantitative differences. The present approach is important because it shows that ivacaftor potentiates WT CFTR in vivo when used as directed. Because of evidence that smoking suppresses CFTR, this finding supports the proposal that ivacaftor could be useful for the treatment of smoking related COPD.

An ivacaftor effect was not detected on sweat chloride levels. Sweat chloride levels were not decreased by ivacaftor in these non-CF subjects. This is not surprising for two reasons. First, sweat chloride provides a logarithmic readout of CFTR function, falling steeply from ~100 mM when CFTR function is zero to ~40 mM.
when CFTR function is ~10% and becoming less sensitive thereafter, so that non-CF subjects can barely be distinguished from CF carriers, who have only 50% WT CFTR function.40 The increase in WT CFTR function we saw is predicted to decrease sweat chloride values by only ~3 mM (extrapolated from Fig. 14 in Char et al.52), consistent with the nearly identical values that we observed off and on drug. Second, it is possible that ivacaftor cannot increase WT CFTR function in the duct, where CFTR is fully activated22, and its high density may push its Po even higher31.

Ivacaftor did not significantly alter M-sweat. A recurring question is whether cholinergically-stimulated M-sweat, which persists in CF subjects, is completely CFTR-independent. Although we did not detect a significant ivacaftor effect on M-sweating (Table 1 and Fig. 4c), it is likely that CFTR does make a minor contribution to M-sweating. CFTR and calcium-activated chloride channels are co-localized in the same sweat coil secretory cells31 (and shown in Fig. 2), and reduced cholinergic sweat rates are seen for CF subjects in some37–39, but not all40 studies. CFTR contributes to cholinergically-mediated fluid secretion in several tissues and species41–49, and stimulating M3 muscarinic receptors in CFTR-transfected BHK cells40 or P2Y receptors via apical UTP in well-differentiated airway cells41 activates CFTR. Ivacaftor provides a tool to measure the participation of CFTR in cholinergically induced M-sweat in CF subjects whose CFTR mutations show large increases to ivacaftor. For example, in an R117H-7T subject where ivacaftor produced an estimated 3–7-fold increase in Po, M-sweating was also significantly increased52. In these non-CF subjects we may have failed to detect a contribution of CFTR on M-sweat because ivacaftor increased CFTR function by 13–41% in these experiments, versus the ~500% increase seen in the R117H-7T subject31.

Advantages/disadvantages of the assay and limitations of the study design. This assay is technically challenging, but provides an accurate and near-linear assessment of CFTR function in vivo, and multiple measures obtained through repeat visits provide sufficient data to detect small differences in function using a small set of subjects. The technical demands will likely limit its use to research settings, where the approach can be useful in calibrating biomarkers used in clinical settings (see for example Graeber et al.51).

This research benefitted from several distinct advantages that helped us estimate the relevant fixed effects (e.g., the drug effect on C-sweat) with greater accuracy by taking account of random variation across glands, testing occasions (weeks), and subjects. First, ivacaftor is a highly specific drug that binds CFTR directly. Second, C-sweat depends absolutely on CFTR22 and varies nearly linearly with CFTR function38,29. Third, we used a method in which two sets of identified glands (left and right arms) were independently stimulated on multiple test days for all but one subject, and for comparison we also activated a separate cholinergic pathway that is not CFTR-dependent.

This study also had important limitations. It was not a placebo controlled, double blind trial. Also, it is clear in retrospect that the experiments looking for peak-trough and washout effects would have been more sensitive if they had been run using 1% cocktail. The small number of subjects could also be considered a limitation, but one purpose of the study was to determine if the multiple gland, within-subject design would reveal a clear signal with a small number of subjects. In this respect, our study was reasonably successful.

Summary and Conclusions. In summary, 4 days of oral ivacaftor produced increases in WT CFTR function that were most reliably detected with C-sweat rate assays conducted with sub-maximal β-adrenergic stimuli, less reliably detected with C-sweat rate assays conducted with maximal stimuli, and not detected with M-sweat measurements or sweat chloride assays. When a drug that is efficacious in vitro fails to show in vivo effects it is commonly interpreted to mean that the drug has failed, but the present results show that real effects can be masked by features of the in vivo measurements used. This point applies especially to the ‘gold standard’ measure of FEV1, which is strongly influenced by environmental factors and is insensitive to improved CFTR function especially at early or late stages of disease. For a discussion of biomarkers as surrogate endpoints, see De Boeck et al.54; and, for a comparison of various biomarker responses to CFTR modulators, see Graeber et al.51.

References

1. Van Goor, F. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proceedings of the National Academy of Sciences of the United States of America 106, 18825–18830 (2009).

2. Yu, H. et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 11, 237–245, https://doi.org/10.1016/j.jcf.2011.12.005 (2012).

3. Accurso, F. J. et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. The New England journal of medicine 363, 1991–2003, https://doi.org/10.1056/NEJMoa0909825 (2010).

4. Ramsey, B. W. et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. The New England journal of medicine 365, 1663–1672, https://doi.org/10.1056/NEJMoa1105185 (2011).

5. McCarty, M. E. & Nielson, D. W. Normalization of sweat chloride concentration and clinical improvement with ivacaftor in a patient with cystic fibrosis with mutation S549N. Chest 144, 1376–1378, 1742106 [pii] (2013).

6. Harrison, M. J., Murphy, D. M. & Plant, B. J. Ivacaftor in a G551D homozygote with cystic fibrosis. The New England journal of medicine 369, 1280–1282, https://doi.org/10.1056/NEJMc1213881 (2013).

7. Eckford, P. D., Li, C., Ramjeesingh, M. & Bear, C. E. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem 287, 36639–36649, M112.393637 (2012).

8. Jih, K. Y. & Hwang, T. C. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proceedings of the National Academy of Sciences of the United States of America 110, 4404–4409, 1215982110 (2013).

9. Veit, G. et al. Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Science translational medicine 6, 246ra297, https://doi.org/10.1126/scitranslmed.3008889 (2014).

10. Cholon, D. M. et al. Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR in cystic fibrosis. Science translational medicine 6, 246ra296, https://doi.org/10.1126/scitranslmed.3008680 (2014).
41. Shamsuddin, A. K., Reddy, M. M. & Quinton, P. M. Iontophoretic beta-adrenergic stimulation of human sweat glands: possible assay for cystic fibrosis homozygous for the F508del-CFTR mutation. *Toxicon* **67**, 12–18, thoraxin-11-200393 (2012).

42. Kharrazii, M., Millia, C. & Wine, J. Sweat chloride testing: controversies and issues. *Lancet Respir Med* **4**, 605–607, https://doi.org/10.1016/S2213-2600(16)30182-5 (2016).

43. Boyle, M. P. et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phenotypic CFTR mutation: a phase 2 randomised controlled trial. *Lancet Respir Med* **2**, 527–538, https://doi.org/10.1016/S2213-2600(14)70132-8 (2014).

44. Reddy, M. M. & Quinton, P. M. Localization of Cl− conductance in normal and Cl− impermeability in cystic fibrosis sweat duct epithelium. *The American journal of physiology* **257**, C727–733, https://doi.org/10.1152/ajpphysiol.1989.257.4.C727 (1989).

45. Bijman, J. et al. Altered intestinal chloride transport in cystic fibrosis. *Pediatric research* **30**, 1321–1327 (1991).

46. Reddy, M. M. & Quinton, P. M. cAMP activation of CF-affected Cl− conductance in both cell membranes of an absorptive cell line. *The Journal of membrane biology* **130**, 49–62 (1992).

47. Joo, N. S., Cho, H. J., Khansaheb, M. & Wine, J. J. Hyposecretion of fluid from tracheal submucosal glands of CFTR-deficient pigs. *J Cyst Fibros* **9**, 25, https://doi.org/10.1016/j.jcf.2014.05.007 (2014).

48. Cho, H. J., Joo, N. S. & Wine, J. J. Defective fluid secretion from submucosal glands of nasal turbinates from CFTR-deficient pigs. *J Cyst Fibros* **10**, 545–549 (1999).

49. Clancy, J. P. et al. Results of a phase Ia study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. *Therapy* **67**, 12–18, thoraxin-11-200393 (2012).

50. Sun, X. et al. Disease phenotype of a ferritin CFTR knockdown model of cystic fibrosis. *Journal of Clinical Investigation* **120**, 3149–3160 (2010).

51. Billett, A., Luo, Y., Balghi, H. & Hanrahan, J. W. Role of tyrosine phosphorylation in the muscarinic activation of the cystic fibrosis transmembrane conductance regulator (CFTR). *J Biol Chem* **288**, 21815–21823, https://doi.org/10.1074/jbc.M113.479360 (2013).
51. Namkung, W., Finkbeiner, W. E. & Verkman, A. S. CFTR-adenylyl cyclase I association responsible for UTP activation of CFTR in well-differentiated primary human bronchial cell cultures. Molecular biology of the cell 21, 2639–2648 (2010).
52. Char, J. E. et al. The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements. PLoS ONE 12, e0175486, https://doi.org/10.1371/journal.pone.0175486 (2017).
53. Graeber, S. Y. et al. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. American journal of respiratory and critical care medicine 197, 1433–1442, https://doi.org/10.1164/rccm.201710-1983OC (2018).
54. De Boeck, K. et al. CFTR biomarkers: time for promotion to surrogate end-point? Eur Respir J 41, 203–216, https://doi.org/10.1183/09031936.00057512 (2013).
55. Reddy, M. M., Bell, C. L. & Quinton, P. M. Evidence of two distinct epithelial cell types in primary cultures from human sweat gland secretory coil. The American journal of physiology 262, C891–898 (1992).
56. Reddy, M. M. & Bell, C. L. Distinct cellular mechanisms of cholinergic and beta-adrenergic sweat secretion. The American journal of physiology 271, C486–494 (1996).
57. Sato, K., Ohtsuyama, M. & Sato, F. Whole cell K and Cl currents in dissociated eccrine secretory coil cells during stimulation. The journal of membrane biology 134, 93–106 (1993).

Acknowledgements
We are grateful to the subjects who participated in these trials. We thank Fred van Goor and Paul Negulescu for critical discussions; Nam Soo Joo and Eric Frisbee for assistance, and members of the CFFT Sweat Consortium organized by Elizabeth Joseloff for comments and intellectual support. We are grateful to Meagan Shinbashi for help in editing and submitting the manuscript. Supported by an Investigator Initiated Grant from Vertex Pharmaceuticals to R.B.M., with additional support from Cystic Fibrosis Research Inc. and Cystic Fibrosis Foundation Therapeutics to J.J.W. Kalydeco was provided by Vertex Pharmaceuticals.

Author Contributions
J.J.W. and R.B.M. designed studies. J.K., M.F., and J.J.W. conducted experiments. J.K., M.F., C.E.D., C.E.M., R.I.H., E.A.C.T., R.B.M., J.J.W. analyzed data; E.A.C.T. and R.I.H. constructed and tested statistical models in lme4. J.J.W., R.B.M. and E.A.C.T. wrote the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-34308-8.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018